FDA approval, a clinical trial listing, and FDA registration are three different regulatory statuses, and clinic marketing often blurs them together. FDA approval means the agency reviewed safety and effectiveness evidence and licensed a product for a specific use. A clinical trial listing or FDA registration alone does not mean a treatment has been approved, reviewed, or proven safe.
Here’s the everyday version of that confusion. A friend forwards you a clinic’s website offering a stem cell injection for knee pain. The page uses three phrases in the same paragraph: “FDA-registered,” “part of an ongoing clinical trial,” and “listed on ClinicalTrials.gov.” Each phrase sounds official. As you’ll see below, none of them, on its own, tells you whether the product is legal to sell, whether it works, or whether the government has reviewed it for safety.
This guide breaks down what FDA approval, clinical trial status, and FDA registration each actually mean, using guidance the FDA has published specifically for consumers evaluating regenerative medicine offers. It isn’t a recommendation for or against any specific treatment. It’s a way to keep clinic marketing language from doing your thinking for you.
What Does “FDA-Approved” Mean for a Regenerative Medicine Product?
FDA approval means the agency has reviewed evidence on a product’s safety and effectiveness and licensed it for a specific, defined use. According to the FDA, most regenerative medicine products need this licensure or approval before they can be marketed to consumers at all.
That category includes products like stem cells, stromal vascular fraction (a substance extracted from body fat), umbilical cord blood, amniotic fluid, and exosomes (tiny particles released by cells). Getting approval for one of these products isn’t a paperwork step. The FDA states that before approval, these products require FDA oversight during a clinical trial — meaning the agency reviews and monitors the trial itself, not just the final results.
A product that hasn’t gone through that process is, in the FDA’s own framing, unapproved. Unapproved does not automatically mean unsafe or worthless. It means the specific safety and effectiveness review the law requires has not happened for that product, for that use.
The FDA also notes that unapproved regenerative products are frequently marketed for serious conditions, including autism, macular degeneration, blindness, chronic pain, multiple sclerosis, ALS, Alzheimer’s disease, heart disease, COPD, and orthopedic conditions. Naming a serious condition doesn’t change a product’s approval status one way or the other.
What Counts as a Legitimate Clinical Trial?
A legitimate clinical trial, in the FDA-oversight sense, is a structured, monitored study conducted under an application the FDA has reviewed. That’s the pathway meant to generate the safety and effectiveness data an approval decision is based on — the agency isn’t just told the results afterward, it’s involved in overseeing how the trial runs.
The word “trial” itself isn’t a protected or regulated label the way “FDA-approved” is. A clinic can describe an offering as a “clinical trial” or a “study” in its own marketing without that offering ever being reviewed or monitored by the FDA. The word alone doesn’t confirm anything about oversight. What matters is who is running the trial, whether it operates under FDA review, and whether you’re being asked to pay for something the agency would classify as investigational (still being tested, not yet approved) rather than approved.
Does Being Listed on ClinicalTrials.gov Mean a Treatment Is Approved?
No. ClinicalTrials.gov is a public registry where trial sponsors can list a study, including basic details like its status and location. A listing tells you a study has been recorded in the database. It does not, by itself, tell you the study is well-designed, that the FDA is overseeing it, or that the product involved is approved for any use.
The FDA is direct about this specific confusion, because it says the confusion is common enough to warn consumers about. In its consumer guidance, the agency states that patients are sometimes referred to ClinicalTrials.gov, or told a product is “registered with FDA,” specifically to suggest the product complies with FDA law — and the FDA says this suggestion is often false. The agency’s own wording: inclusion of a product in the ClinicalTrials.gov database, or a firm’s registration and listing with the FDA, does not mean the product is legally marketed.
That distinction matters because it’s easy to hear “registered” and assume it means “approved.” They are not the same regulatory status, and clinic marketing sometimes relies on that assumption going unquestioned.
What Does “FDA-Registered” Actually Mean?
FDA registration, in many contexts, is closer to an address book entry than a safety review. A company can register an establishment or list a product with the FDA as a required administrative step, without that step involving any FDA evaluation of whether the product is safe or effective for a given use.
Registration and listing are not the same regulatory action as approval or licensure, and the FDA has said so explicitly in its consumer materials on this exact topic. This site’s research approach treats FDA regulatory and enforcement guidance as the top tier of evidence for exactly this reason: it’s the source that draws these distinctions in plain terms, rather than leaving readers to guess what a marketing phrase implies.
FDA Approval, FDA Registration, and Clinical Trial Listing: How They Differ
These three terms get used almost interchangeably in clinic marketing. They are not interchangeable. Here’s what each one actually confirms, and what it doesn’t:
- FDA approval or licensure: Confirms the FDA reviewed safety and effectiveness evidence for a specific use and authorized the product to be marketed for that use. Does not mean every claim a clinic makes about the product is accurate.
- FDA registration or listing: Confirms a company completed a required administrative step, such as registering a manufacturing establishment or listing a product. Does not mean the FDA evaluated the product’s safety or effectiveness.
- Clinical trial listing on ClinicalTrials.gov: Confirms a sponsor recorded a study in the public registry. Does not mean the FDA is overseeing that trial, and does not mean the product being studied is approved for any use.
- Use of the word “trial” in clinic marketing: Confirms nothing on its own. Any offering can be called a trial or a study. Only independent verification — asking who oversees it and whether the FDA reviews it — confirms what kind of trial it actually is.
What Warning Sign Does the FDA Specifically Name?
The FDA points to one practical red flag: if you’re being charged for one of these unapproved regenerative products outside of a properly overseen clinical trial, the agency says you are likely being offered that product illegally. Payment itself isn’t proof of fraud in every single case, but the FDA treats being asked to pay, outside a legitimate FDA-overseen trial, as a meaningful warning sign worth stopping to examine before you go further.
What Questions Should You Ask Before You Pay for a Regenerative Treatment?
You don’t need a medical or legal background to ask these questions. Bring this list to any consultation, and treat a vague or dismissive answer to any step as a reason to slow down rather than proceed.
- Name the exact product. Ask what it’s called, what it’s derived from, and whether the FDA has approved or licensed it for the specific use you’re being offered — not just “regenerative medicine” in general terms.
- Ask who is overseeing the trial, if one is mentioned. A trial name or number isn’t enough on its own. Ask whether the FDA reviews and monitors this specific trial, and ask to see documentation rather than a verbal assurance.
- Ask directly whether you would be paying to participate. If the answer is yes, and the offering is outside an FDA-overseen trial, treat that as the specific warning sign the FDA has named above.
- Ask what “registered” or “listed” refers to. FDA registration and ClinicalTrials.gov listing are administrative facts, not approval decisions. Ask the clinic to clarify which one they mean, and get the answer in writing if possible.
- Ask how problems are tracked and reported. Ask what happens if you have a reaction, who is responsible for reporting it, and how that reporting works for this specific offering.
- Take the answers to an independent clinician. A second medical opinion, from someone not affiliated with the clinic offering the product, is one of the most reliable ways to pressure-test marketing claims before you commit money or your body to a procedure.
What Should You Do If You Think You Were Misled?
The FDA provides a direct channel for exactly this situation. Consumers can contact the FDA’s Office of Combination Products at ocod@fda.hhs.gov, and adverse effects from any product can be reported through the FDA’s MedWatch Adverse Event Reporting program. Reporting doesn’t require certainty that something illegal happened — it’s the mechanism the FDA itself points consumers toward when marketing language and a product’s actual regulatory status don’t line up.
If you’re working through a broader evaluation of a regenerative medicine claim rather than just this question, Start Here walks through a four-step framework for separating credible research from unproven treatment offers. The site’s editorial policy also explains why this publication sources regulatory claims directly from agencies like the FDA rather than from clinic marketing materials.
Frequently Asked Questions
Does FDA registration mean a regenerative medicine product is safe or approved?
No. FDA registration is an administrative step, such as registering a manufacturing establishment or listing a product. The FDA has stated directly that registration and listing do not mean a product is legally marketed or that it has been evaluated for safety or effectiveness.
If a treatment is listed on ClinicalTrials.gov, does that mean the FDA is overseeing it?
Not necessarily. A ClinicalTrials.gov listing confirms a sponsor recorded the study in the public registry. The FDA has specifically warned that patients are sometimes told a product is registered or listed to imply FDA compliance, and says that implication is often false.
Is it legal for a clinic to charge me for a stem cell treatment?
It depends on the product’s approval status and whether the offering is part of a legitimate, FDA-overseen clinical trial. The FDA states that if you’re being charged for an unapproved regenerative product outside of such a trial, you are likely being offered that product illegally.
What conditions are commonly targeted by unapproved regenerative medicine marketing?
The FDA lists autism, macular degeneration, blindness, chronic pain, multiple sclerosis, ALS, Alzheimer’s disease, heart disease, COPD, and orthopedic conditions among the uses for which unapproved products are frequently marketed. Naming a serious condition does not change a product’s actual approval status.
Where do I report a clinic I think is misrepresenting FDA approval or trial status?
You can contact the FDA’s Office of Combination Products at ocod@fda.hhs.gov. Adverse effects from any product can also be reported through the FDA’s MedWatch Adverse Event Reporting program.
Educational Information Disclaimer
This article is educational information only. It is not medical advice, and it does not replace a conversation with a qualified, independent clinician about any specific procedure, product, or diagnosis. See the site’s full medical information disclaimer for more detail. Regenerative Evidence Guide is an independent educational publication and is not affiliated with any clinic, product manufacturer, academy, faculty, conference, or training program, including any organization formerly associated with this domain. If you experience an unexpected reaction to any treatment, contact your clinician or, for a medical emergency, your local emergency services immediately.
Sources: U.S. Food and Drug Administration, “Important Patient and Consumer Information About Regenerative Medicine Therapies”; ClinicalTrials.gov, “Learn About Studies”. Last updated September 7, 2026.
By Regenerative Evidence Guide Editorial Team
Leave a Reply